Inhibikase Back In Game As FDA Lifts Hold On Multiple System Atrophy Drug

The US FDA lifted a clinical hold that it had placed in November after reviewing the company’s INDs to start Phase IIa studies in MSA and Parkinson’s, which was the subject of a hold lifted in January.

The FDA lifted a full clinical hold on Inhibikase's MSA program • Source: Shutterstock

Inhibikase Therapeutics, Inc. is back in the race to develop a drug to treat multiple system atrophy (MSA) now that the US Food and Drug Administration has lifted a full clinical hold on IkT-148009, after having already lifted the hold for Parkinson’s disease.

The company announced on 8 March that the FDA had lifted the hold it placed on its investigational new drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D